- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04424979
Feasibility Tests for Various Prism Configurations for Visual Field Loss
Visual Field Expansion Through Innovative Multi-Periscopic Prism Design
The investigators will develop and test different configurations of high-power prisms to expand the field of vision of patients with visual field loss to assist them with obstacle detection when walking. The study will involve multiple visits (typically four) to Schepens Eye Research Institute for fitting and testing with the prism glasses. The overall objective is to determine best designs and fitting parameters for implementation in prism devices for future clinical trials.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Schepens Eye Research Institute
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Visual field loss, either peripheral field loss or hemianopic field loss
- Visual acuity of at least 20/50 in the better eye
- In sufficiently good health to be able to complete sessions lasting 2-4 hours
- Able to independently walk short distances
- Able to give voluntary, informed consent
- Able to speak English
Exclusion Criteria:
- Any physical or mental impairments, including cognitive dysfunction, balance problems or other deficits that could impair the ability to walk or use the prism spectacles
- A history of seizures in the last 6 months
- Hemispatial neglect (subjects with hemianopic field loss only)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Device Feasibility
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: High power prisms
Various configurations of high power prisms will be developed for each individual and custom fit into spectacles lenses. |
High power prisms designed to shift images from blind areas into portions of the wearer's remaining, seeing, field of vision |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Field of view expansion
Time Frame: Through study completion, an average of four months
|
Horizontal and vertical extent of the expansion (in degrees) of the field of view |
Through study completion, an average of four months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Pedestrian detection rate
Time Frame: Through study completion, an average of four months
|
Proportion of pedestrians detected (in simulated walking or simulated driving) |
Through study completion, an average of four months
|
Collaborators and Investigators
Collaborators
Investigators
- Study Director: Eliezer Peli, MSc, OD, Schepens Eye Research Institute of Massachusetts Eye and Ear
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- MPP_Feasibility1
- R01EY023385 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.